Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd

Please reload

Recent Posts

LIfT BioSciences Wins the Support of The European Institute for Innovation & Technology

February 12, 2019

1/7
Please reload

Featured Posts

LIfT BioSciences signals a new dawn in Cancer Therapy at The Prostate Cancer Foundation Retreat

February 12, 2019

 

Alex Blyth, CEO of LIfT BioSciences, delivered the closing presentation for The 25th Prostate Cancer Foundation Retreat in Carlsbad, USA to an audience of the world's leading experts and authorities on Prostate Cancer.

 

The presentation solidified Innate Cell Therapies as the next game changer in the fight against Prostate Cancer and other solid tumours. Strikingly, not a single member of the audience when asked, challenged Alex Blyth's assertion that "the primary reasons most people do not get cancer was not about their adaptive immune system, as the current industry focus in this area might have us believe, but innate immunity".

 

Alex Blyth commented afterwards that "Challenging the status quo to bring a new consensus of opinion about the causes of solid tumours helps to focus research efforts and investment into those areas most likely to save lives in the future. There is a need to move to innate therapies that have broad rather than targeted MOA's so that they can destroy tumours irrespective of strain or mutation. This is a controversial statement but we believe that we are on the right path and we are encouraging thought leaders to support this."  

 

The Prostate Cancer Foundation's (PCF) 25th Annual Scientific Retreat, uncovered the most compelling and promising new research that may lead to new treatments for men with prostate cancer, much of which was proudly funded by PCF's Research Enterprise. This was also a special year, as PCF celebrated a quarter-century of the tremendous cancer research and treatment progress that has been realized since PCF was founded in 1993, which includes a ~50% reduction in the prostate cancer mortality rate. The event welcomed LIfT BioSciences into the "PCF research family".

Share on Facebook
Share on Twitter
Please reload

Follow Us

I'm busy working on my blog posts. Watch this space!

Please reload

Search By Tags